GFR-话题@MedSci

#GFR#

483篇内容 | 2550人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534460, encodeId=775a15344608d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=泰瑞沙是**一个单药一线治疗让EGFR突变晚期非小细胞肺癌中位总生存期超过3年的药物, objectType=article, longId=180287, objectId=3dc318028eda, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc318028eda, replyNumber=0, likeNumber=94, createdTime=2019-10-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc318028eda, moduleTitle=泰瑞沙是**一个单药一线治疗让EGFR突变晚期非小细胞肺癌中位总生存期超过3年的药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc318028eda)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534459, encodeId=bf12153445939, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗, objectType=article, longId=180183, objectId=e8d718018362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8d718018362, replyNumber=0, likeNumber=69, createdTime=2019-09-29, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8d718018362, moduleTitle=NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8d718018362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534458, encodeId=08431534458aa, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JAMA Oncology：二甲双胍抗癌实锤！临床试验证实，二甲双胍+靶向药一线治疗，可将携带EGFR突变晚期肺癌患者的生存期延长14个月, objectType=article, longId=180022, objectId=5bda180022ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bda180022ac, replyNumber=0, likeNumber=78, createdTime=2019-09-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bda180022ac, moduleTitle=JAMA Oncology：二甲双胍抗癌实锤！临床试验证实，二甲双胍+靶向药一线治疗，可将携带EGFR突变晚期肺癌患者的生存期延长14个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bda180022ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534457, encodeId=002f153445e5b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Sci Rep：Myoferlin沉默能够抑制VEGFR2介导的转移透明细胞肾细胞癌增殖, objectType=article, longId=179593, objectId=e0931e95934d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0931e95934d, replyNumber=0, likeNumber=90, createdTime=2019-09-18, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0931e95934d, moduleTitle=Sci Rep：Myoferlin沉默能够抑制VEGFR2介导的转移透明细胞肾细胞癌增殖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0931e95934d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534456, encodeId=b4d4153445635, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=2019 WCLC ∣奥希替尼160mg为EGFR T790M突变阳性伴CNS转移NSCLC患者带来显著获益, objectType=article, longId=179499, objectId=164d1e9499e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=164d1e9499e1, replyNumber=0, likeNumber=70, createdTime=2019-09-17, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=164d1e9499e1, moduleTitle=2019 WCLC ∣奥希替尼160mg为EGFR T790M突变阳性伴CNS转移NSCLC患者带来显著获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=164d1e9499e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534455, encodeId=9b26153445587, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=捷报频传！张力教授团队再次报道肺癌EGFR 20ins治疗新方案：奥希替尼+西妥昔单抗成为潜力之选！, objectType=article, longId=179495, objectId=b44d1e9495ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b44d1e9495ef, replyNumber=0, likeNumber=61, createdTime=2019-09-17, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b44d1e9495ef, moduleTitle=捷报频传！张力教授团队再次报道肺癌EGFR 20ins治疗新方案：奥希替尼+西妥昔单抗成为潜力之选！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b44d1e9495ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534454, encodeId=cfe0153445494, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=NMPA授予Tagrisso（osimertinib）上市许可，治疗EGFR突变的非小细胞肺癌, objectType=article, longId=178988, objectId=c2d11e898883, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2d11e898883, replyNumber=0, likeNumber=54, createdTime=2019-09-07, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2d11e898883, moduleTitle=NMPA授予Tagrisso（osimertinib）上市许可，治疗EGFR突变的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2d11e898883)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534453, encodeId=0d0d1534453ef, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=中国监管机构批准阿斯利康的Tagrisso作为EGFR突变型NSCLC的一线治疗药物, objectType=article, longId=178850, objectId=de591e885009, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de591e885009, replyNumber=0, likeNumber=58, createdTime=2019-09-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de591e885009, moduleTitle=中国监管机构批准阿斯利康的Tagrisso作为EGFR突变型NSCLC的一线治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de591e885009)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534452, encodeId=142515344527c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=系统比较**、二、三代EGFR-TKI，综合实力奥希替尼更胜一筹, objectType=article, longId=178672, objectId=fd2a1e867284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd2a1e867284, replyNumber=0, likeNumber=66, createdTime=2019-09-04, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd2a1e867284, moduleTitle=系统比较**、二、三代EGFR-TKI，综合实力奥希替尼更胜一筹, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd2a1e867284)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534451, encodeId=7fd9153445109, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=【CNS学院·大咖说】刘安文教授： EGFR突变阳性晚期NSCLC脑转移防治策略, objectType=article, longId=178512, objectId=7fb11e8512e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fb11e8512e3, replyNumber=0, likeNumber=71, createdTime=2019-09-02, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fb11e8512e3, moduleTitle=【CNS学院·大咖说】刘安文教授： EGFR突变阳性晚期NSCLC脑转移防治策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fb11e8512e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534450, encodeId=0725153445099, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Oncol：Rogaratinib治疗多种FGFR mRNA高表达晚期肿瘤, objectType=article, longId=177581, objectId=565d1e7581d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=565d1e7581d5, replyNumber=0, likeNumber=0, createdTime=2019-08-15, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=565d1e7581d5, moduleTitle=Lancet Oncol：Rogaratinib治疗多种FGFR mRNA高表达晚期肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=565d1e7581d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534449, encodeId=1563153444986, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=喜大普奔 | III期FLAURA 研究OS取得阳性结果，EGFR突变晚期非小细胞肺癌一线标准治疗已成定论, objectType=article, longId=177574, objectId=06bb1e7574a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06bb1e7574a5, replyNumber=0, likeNumber=0, createdTime=2019-08-15, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06bb1e7574a5, moduleTitle=喜大普奔 | III期FLAURA 研究OS取得阳性结果，EGFR突变晚期非小细胞肺癌一线标准治疗已成定论, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06bb1e7574a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534448, encodeId=45cf1534448b3, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, objectType=article, longId=177383, objectId=b6d81e73834c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6d81e73834c, replyNumber=0, likeNumber=62, createdTime=2019-08-12, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6d81e73834c, moduleTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6d81e73834c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534447, encodeId=fcc7153444e22, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=“三代同堂”谁领风骚？EGFR-TKI一线疗效和安全性大比拼, objectType=article, longId=176915, objectId=b5e21e691585, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5e21e691585, replyNumber=0, likeNumber=59, createdTime=2019-08-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5e21e691585, moduleTitle=“三代同堂”谁领风骚？EGFR-TKI一线疗效和安全性大比拼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5e21e691585)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534446, encodeId=97c0153444694, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JASN：强化降压引起的早期eGFR下降对心血管结局的影响, objectType=article, longId=176026, objectId=b7be1e6026d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7be1e6026d4, replyNumber=0, likeNumber=71, createdTime=2019-07-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7be1e6026d4, moduleTitle=JASN：强化降压引起的早期eGFR下降对心血管结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7be1e6026d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534445, encodeId=05cf153444584, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EGFR敏感突变晚期NSCLC患者的TKI治疗策略, objectType=article, longId=175265, objectId=8f8b1e5265b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f8b1e5265b4, replyNumber=0, likeNumber=70, createdTime=2019-07-13, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f8b1e5265b4, moduleTitle=EGFR敏感突变晚期NSCLC患者的TKI治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f8b1e5265b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534444, encodeId=5a8c153444451, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗, objectType=article, longId=175233, objectId=c5631e5233ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5631e5233ba, replyNumber=0, likeNumber=55, createdTime=2019-07-13, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5631e5233ba, moduleTitle=BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5631e5233ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534443, encodeId=edb21534443e8, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=陈良安教授：EGFR敏感突变晚期NSCLC治疗策略, objectType=article, longId=175124, objectId=eb5f1e51243e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb5f1e51243e, replyNumber=0, likeNumber=68, createdTime=2019-07-12, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb5f1e51243e, moduleTitle=陈良安教授：EGFR敏感突变晚期NSCLC治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb5f1e51243e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534442, encodeId=b0a2153444288, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=英国NICE推荐将辉瑞的Vizimpro用于治疗EGFR阳性的非小细胞肺癌患者, objectType=article, longId=174933, objectId=51dc1e4933dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51dc1e4933dc, replyNumber=0, likeNumber=66, createdTime=2019-07-08, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51dc1e4933dc, moduleTitle=英国NICE推荐将辉瑞的Vizimpro用于治疗EGFR阳性的非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51dc1e4933dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534441, encodeId=acd81534441fa, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EGFR Exon 20突变和HER2突变型NSCLC治疗的新选择, objectType=article, longId=174827, objectId=79f81e482728, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79f81e482728, replyNumber=0, likeNumber=68, createdTime=2019-07-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79f81e482728, moduleTitle=EGFR Exon 20突变和HER2突变型NSCLC治疗的新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79f81e482728)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

泰瑞沙是**一个单药一线治疗让EGFR突变晚期非小细胞肺癌中位总生存期超过3年的药物

2019-10-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗

2019-09-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JAMA Oncology：二甲双胍抗癌实锤！临床试验证实，二甲双胍+靶向药一线治疗，可将携带EGFR突变晚期肺癌患者的生存期延长14个月

2019-09-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Sci Rep：Myoferlin沉默能够抑制VEGFR2介导的转移透明细胞肾细胞癌增殖

2019-09-18

liuyiping (审核中...)

前往app查看评论内容

#GFR#

2019 WCLC ∣奥希替尼160mg为EGFR T790M突变阳性伴CNS转移NSCLC患者带来显著获益

2019-09-17

liuyiping (审核中...)

前往app查看评论内容

#GFR#

捷报频传！张力教授团队再次报道肺癌EGFR 20ins治疗新方案：奥希替尼+西妥昔单抗成为潜力之选！

2019-09-17

liuyiping (审核中...)

前往app查看评论内容

#GFR#

NMPA授予Tagrisso（osimertinib）上市许可，治疗EGFR突变的非小细胞肺癌

2019-09-07

liuyiping (审核中...)

前往app查看评论内容

#GFR#

中国监管机构批准阿斯利康的Tagrisso作为EGFR突变型NSCLC的一线治疗药物

2019-09-06

liuyiping (审核中...)

前往app查看评论内容

#GFR#

系统比较**、二、三代EGFR-TKI，综合实力奥希替尼更胜一筹

2019-09-04

医者仁心 (审核中...)

前往app查看评论内容

#GFR#

【CNS学院·大咖说】刘安文教授： EGFR突变阳性晚期NSCLC脑转移防治策略

2019-09-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Oncol：Rogaratinib治疗多种FGFR mRNA高表达晚期肿瘤

2019-08-15

liuyiping (审核中...)

前往app查看评论内容

#GFR#

喜大普奔 | III期FLAURA 研究OS取得阳性结果，EGFR突变晚期非小细胞肺癌一线标准治疗已成定论

2019-08-15

liuyiping (审核中...)

前往app查看评论内容

#GFR#

阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率

2019-08-12

liuyiping (审核中...)

前往app查看评论内容

#GFR#

“三代同堂”谁领风骚？EGFR-TKI一线疗效和安全性大比拼

2019-08-06

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JASN：强化降压引起的早期eGFR下降对心血管结局的影响

2019-07-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EGFR敏感突变晚期NSCLC患者的TKI治疗策略

2019-07-13

liuyiping (审核中...)

前往app查看评论内容

#GFR#

BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗

2019-07-13

liuyiping (审核中...)

前往app查看评论内容

#GFR#

陈良安教授：EGFR敏感突变晚期NSCLC治疗策略

2019-07-12

liuyiping (审核中...)

前往app查看评论内容

#GFR#

英国NICE推荐将辉瑞的Vizimpro用于治疗EGFR阳性的非小细胞肺癌患者

2019-07-08

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EGFR Exon 20突变和HER2突变型NSCLC治疗的新选择

2019-07-06

科室
- - 订阅+
  - 更多科室
工具
服务